Large holder update, amended
Open the filing on sec.gov
Jupiter Neurosciences, Inc. (JUNS)
Nasdaq: JUNS · Pharmaceutical Preparations · Jupiter, FL · filing with the SEC since 2016
The companyfiscal 2025, as filed
Revenue$21,796
Net income-$8.6M-254.4%
Earnings per share$-0.25-212.5%
Operating cash flow-$5.4M-38.4%
Cashn/a
Debtn/a
Shareholders’ equity-$1.8M-143.9%
Shares, diluted34.6M+20.3%
Return on equityn/a
The recordfrom its filings
Filings in 202668
Newest filingOct 26 · SCHEDULE 13G/A
Annual reportApr 1, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted0
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$9.2MCash from operations -$7.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Employee stock plan registration
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Private placement notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.